FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the...

Related Keywords

Brussels ,Bruxelles Capitale ,Belgium ,Smyrna ,Izmir ,Turkey ,Erica Puntel ,Antje Witte ,Hidradenitis Suppurativa ,Emmanuel Caeymaex ,Group Of Companies ,Drug Administration ,Ucb Inc ,Twitter ,Immunology Solutions ,Us Communications ,Biologics License Application ,Executive Vice President ,Important Safety Information ,United States ,Herpes Simplex Infections ,Euronext Brussels ,Oral Presentation ,Rev Dis ,Clin Cosmet Investig ,Its Effect ,Study Participants With Moderate ,Severe Hidradenitis Suppurativa ,Ucb ,